DexCom, Inc. vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Direxion Daily Semiconductor Bear 3X Shares trades at $41.05. Which is the better fit depends on your goals.
| DXCM | SOXS | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $89.53 | $1.49K |
52-Week Low | $54.84 | $32.50 |
Enterprise Value | $33.24B | — |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $40.97, down 9.38% today amid volatile semiconductor sector conditions. The technical picture remains bearish with moving averages signaling continued downward pressure, though oversold RSI levels suggest potential for near-term bounce. Recent news highlights SOXS benefiting from AI-fueled tech rally concerns and semiconductor stock sell-offs, with the fund executing a 1:10 stock split effective July 26, 2026.
As a leveraged inverse ETF, SOXS offers amplified exposure to semiconductor sector declines but carries significant decay and volatility risks. The fund's performance is heavily dependent on continued semiconductor weakness, which faces fundamental challenges from AI infrastructure growth and memory chip competition. Investors should understand the complex nature of inverse leveraged products before considering positions.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →